Latest filing published 26 Sept 2022 for Spero Therapeutics, Inc., €3.1M. Read the official filing
Across 17 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Aquilo Capital Management, LLC is a declared insider of Spero Therapeutics, Inc., with filings sourced from SEC (Form 4). The record holds 18 filings, for trades running from 20 August 2021 to 22 September 2022.
In open-market terms, that means 17 purchases worth €13.2M on one side and 1 sale worth €3.1M on the other. On balance, insiders were net buyers of €10.1M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. So far in 2022, the count stands at 10 purchases and 1 sale.
Half of the purchases are above €387k and half below. The 17 purchases reviewed show no overlap with other insiders buying the same stock within a month.
On 26 September 2022 came the latest disclosure, an open-market sale for €3.1M in Spero Therapeutics, Inc. The latest purchase dates back some time: it was published 1,634 days ago, on 28 April 2022. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
18 of 18 declarations